Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:ALKS
- CUSIP: G0176710
- Web: www.alkermes.com
Capitalization:- Market Cap: $7.7397 billion
- Outstanding Shares: 153,656,000
Average Prices:- 50 Day Moving Avg: $51.49
- 200 Day Moving Avg: $56.44
- 52 Week Range: $41.93 - $63.40
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -129.15
- P/E Growth: -1048.75
Sales & Book Value:- Annual Revenue: $804.37 million
- Price / Sales: 9.62
- Book Value: $7.82 per share
- Price / Book: 6.44
Profitability:- EBIDTA: ($103,300,000.00)
- Net Margins: -24.33%
- Return on Equity: -9.12%
- Return on Assets: -6.40%
Debt:- Debt-to-Equity Ratio: 0.23%
- Current Ratio: 3.54%
- Quick Ratio: 3.20%
Misc:- Average Volume: 763,111 shs.
- Beta: 2.23
- Short Ratio: 8.43
Frequently Asked Questions for Alkermes PLC (NASDAQ:ALKS)
What is Alkermes PLC's stock symbol?
Alkermes PLC trades on the NASDAQ under the ticker symbol "ALKS."
How were Alkermes PLC's earnings last quarter?
Alkermes PLC (NASDAQ:ALKS) announced its quarterly earnings data on Thursday, July, 27th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.02. The company earned $218.80 million during the quarter, compared to analyst estimates of $216.54 million. Alkermes PLC had a negative return on equity of 9.12% and a negative net margin of 24.33%. The firm's revenue for the quarter was up 12.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.01) EPS. View Alkermes PLC's Earnings History.
When will Alkermes PLC make its next earnings announcement?
Where is Alkermes PLC's stock going? Where will Alkermes PLC's stock price be in 2017?
8 brokers have issued 12-month price targets for Alkermes PLC's shares. Their forecasts range from $51.00 to $78.00. On average, they expect Alkermes PLC's stock price to reach $63.63 in the next twelve months. View Analyst Ratings for Alkermes PLC.
What are analysts saying about Alkermes PLC stock?
Here are some recent quotes from research analysts about Alkermes PLC stock:
- 1. According to Zacks Investment Research, "Alkermes posted narrower-than-expected loss in the second quarter of 2017 while sales marginally surpassed estimates. Vivitrol and Aristada are anticipated to be primary growth drivers. While, Vivitrol should benefit from the newly passed legislation, CARA, securing reimbursement and access for Aristada also bodes well. The company also plans to submit a new drug application (NDA) for ALKS 5461 in major depressive disorder and expects to complete the pivotal efficacy of ALKS3831 in schizophrenia. However, Alkermes is highly dependent on manufacturing and/or royalty revenues on sales of products that are commercialized by the company’s partners. Given its history of pipeline setbacks, any obstacle in the process of development of the candidates could weigh heavily on the stock. Stiff competition and dependence on partners remains a threat. Moreover, Alkermes’ shares have underperformed the Zacks classified industry year to date." (8/2/2017)
- 2. Cowen and Company analysts commented, "ALKS reported Q1:17 results which came in below expectations." (4/28/2017)
- 3. Cantor Fitzgerald analysts commented, "We remain cautious on ALKS stock because we believe it reasonable that the company may not be able to file for regulatory approval of ALKS 5461 (for treating major depressive disorder, MDD) with data from only one positive Phase 3 trial from the three studies that comprise the FORWARD clinical program. We also remain unconvinced that the company will successfully transition from a developer of drug formulation technologies (historically applied to partner's assets) to a developer of proprietary products. As noted in a report we recently published on the evolving multiple sclerosis (MS) landscape, we believe new market entrants could challenge existing drug franchises, in particular that of Biogen (BIIB, Neutral, $277). Even if ALKS 8700 does not reduce GI side effects relative to that experienced with Tecfidera, we believe ALKS would likely seek approval anyway given the hegemony BIIB enjoys in the MS fumarate drug market." (3/16/2017)
- 4. J P Morgan Chase & Co analysts commented, "Importantly 5461 continued to be well tolerated, in line with prior studies. ALKS plans to meet with the FDA in early 1Q17 to discuss filing, and we continue to think positive FORWARD-5 data makes the totality of the data approvable [...] Further confirmation of an NDA filing based on data in hand, as well as, clarity on the filing timeline will be key in 2017." (10/21/2016)
Who are some of Alkermes PLC's key competitors?
Some companies that are related to Alkermes PLC include Alnylam Pharmaceuticals (ALNY), Seattle Genetics (SGEN), Qiagen N.V. (QGEN), Ionis Pharmaceuticals (IONS), Icon Plc (ICLR), Exact Sciences Corporation (EXAS), Charles River Laboratories International (CRL), United Therapeutics Corporation (UTHR), PRA Health Sciences (PRAH), ACADIA Pharmaceuticals (ACAD), Bio-Techne Corp (TECH), PAREXEL International Corporation (PRXL), Puma Biotechnology (PBYI), FibroGen (FGEN), Nektar Therapeutics (NKTR), WuXi PharmaTech (Cayman) (WX), Portola Pharmaceuticals (PTLA) and Ligand Pharmaceuticals Incorporated (LGND).
Who are Alkermes PLC's key executives?
Alkermes PLC's management team includes the folowing people:
- Richard F. Pops, Chairman, President, and CEO
- James M. (Jim) Frates, SVP, CFO, and Treasurer
- Gordon G. Pugh, SVP, COO, and Chief Risk Officer
- Richard F. Pops, Chairman of the Board, Chief Executive Officer
- Shane M. Cooke, President
- James M. Frates, Chief Financial Officer, Senior Vice President, Treasurer
- Kathryn L. Biberstein, Executive Vice President, Chief Administrative Officer, Chief Compliance Officer, Chief Risk Officer, Secretary
- Elliot W. Ehrich M.D., Executive Vice President - Research and Development and Chief Medical Officer
- Iain M. Brown, Senior Vice President - Finance, Chief Accounting Officer
- David Joseph Gaffin, Senior Vice President, Chief Legal Officer
Who owns Alkermes PLC stock?
Alkermes PLC's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (14.95%), Vanguard Group Inc. (8.17%), BlackRock Inc. (6.65%), Woodford Investment Management Ltd (4.98%), State Street Corp (2.56%) and Franklin Resources Inc. (1.60%). Company insiders that own Alkermes PLC stock include David Joseph Gaffin, David W Anstice, Elliot Ehrich, Gordon G Pugh, Iain Michael Brown, James M Frates, Kathryn L Biberstein, Mark Stejbach, Michael J Landine, Paul J Mitchell, Richard F Pops, Robert A Breyer and Shane Cooke. View Institutional Ownership Trends for Alkermes PLC.
Who sold Alkermes PLC stock? Who is selling Alkermes PLC stock?
Alkermes PLC's stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., Westfield Capital Management Co. LP, Victory Capital Management Inc., BlackRock Inc., Airain ltd, Tamarack Advisers LP, APG Asset Management N.V. and State Street Corp. Company insiders that have sold Alkermes PLC stock in the last year include David Joseph Gaffin, Elliot Ehrich, Gordon G Pugh, James M Frates, Kathryn L Biberstein, Mark Stejbach, Michael J Landine, Paul J Mitchell, Richard F Pops, Robert A Breyer and Shane Cooke. View Insider Buying and Selling for Alkermes PLC.
Who bought Alkermes PLC stock? Who is buying Alkermes PLC stock?
Alkermes PLC's stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Fiera Capital Corp, Vanguard Group Inc., First Trust Advisors LP, Woodford Investment Management Ltd, Macquarie Group Ltd., New York State Common Retirement Fund and FMR LLC. View Insider Buying and Selling for Alkermes PLC.
How do I buy Alkermes PLC stock?
Shares of Alkermes PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alkermes PLC's stock price today?
One share of Alkermes PLC stock can currently be purchased for approximately $50.37.
MarketBeat Community Rating for Alkermes PLC (NASDAQ ALKS)MarketBeat's community ratings are surveys of what our community members think about Alkermes PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Alkermes PLC (NASDAQ:ALKS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 4 Hold Ratings, 4 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | $63.63 (26.32% upside) |
Analysts' Ratings History for Alkermes PLC (NASDAQ:ALKS)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/25/2017 | Jefferies Group LLC | Set Price Target | Buy | $69.00 | Low |  |
| 7/1/2017 | J P Morgan Chase & Co | Set Price Target | Buy | $78.00 | Low | |
| 6/13/2017 | Leerink Swann | Downgrade | Outperform -> Market Perform | $68.00 -> $61.00 | Medium | |
| 6/7/2017 | Credit Suisse Group | Reiterated Rating | Buy | $70.00 | Low | |
| 4/28/2017 | Cowen and Company | Reiterated Rating | Buy | | Low | |
| 4/24/2017 | Morgan Stanley | Reiterated Rating | Equal Weight | $62.00 | Low | |
| 3/16/2017 | Cantor Fitzgerald | Reiterated Rating | Neutral | $51.00 | Medium | |
| 9/27/2016 | Citigroup Inc. | Boost Price Target | Neutral | $44.00 -> $53.00 | N/A | |
| 7/29/2016 | Barclays PLC | Boost Price Target | Overweight | $65.00 -> $66.00 | N/A | |
| 5/26/2016 | Evercore ISI | Initiated Coverage | Buy | $59.00 | N/A | |
| 2/22/2016 | Goldman Sachs Group, Inc. (The) | Lower Price Target | | $57.00 -> $35.00 | N/A | |
| 1/21/2016 | Guggenheim | Reiterated Rating | Hold | | N/A | |
(Data available from 9/24/2015 forward)
Earnings History for Alkermes PLC (NASDAQ:ALKS)Earnings History by Quarter for Alkermes PLC (NASDAQ ALKS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/31/2017 | | $0.01 | | | | | N/A | |
| 7/27/2017 | 6/30/2017 | ($0.01) | $0.01 | $216.54 million | $218.80 million | View | N/A | |
| 4/27/2017 | 3/31/2017 | ($0.24) | ($0.31) | $195.79 million | $191.80 million | View | N/A | |
| 2/15/2017 | Q416 | $0.04 | $0.15 | $206.38 million | $213.50 million | View | Listen | |
| 11/2/2016 | Q316 | ($0.06) | ($0.09) | $186.39 million | $180.20 million | View | Listen | |
| 7/28/2016 | Q216 | ($0.10) | ($0.01) | $174.15 million | $195.20 million | View | Listen | |
| 4/28/2016 | Q116 | ($0.20) | ($0.16) | $153.64 million | $156.80 million | View | Listen | |
| 2/25/2016 | Q415 | ($0.18) | ($0.15) | $161.24 million | $163.10 million | View | Listen | |
| 10/29/2015 | Q315 | ($0.21) | ($0.18) | $151.77 million | $152.70 million | View | Listen | |
| 7/30/2015 | Q215 | ($0.10) | ($0.09) | $142.80 million | $151.40 million | View | Listen | |
| 4/30/2015 | Q115 | ($0.03) | $0.06 | $146.60 million | $161.20 million | View | Listen | |
| 2/24/2015 | Q414 | $0.04 | $0.11 | $161.70 million | $175.20 million | View | Listen | |
| 10/29/2014 | Q314 | ($0.12) | ($0.13) | $155.53 million | $160.00 million | View | Listen | |
| 7/31/2014 | Q314 | $0.04 | ($0.01) | $146.91 million | $153.40 million | View | Listen | |
| 4/30/2014 | Q1 | $0.10 | $0.11 | $135.79 million | $130.21 million | View | Listen | |
| 2/27/2014 | Q114 | $0.20 | $0.27 | $142.93 million | $154.50 million | View | Listen | |
| 10/31/2013 | | $0.22 | $0.22 | $137.35 million | $139.80 million | View | Listen | |
| 7/25/2013 | Q1 2014 | $0.22 | $0.30 | $131.50 million | $138.60 million | View | Listen | |
| 5/23/2013 | Q4 2013 | $0.17 | $0.40 | $128.01 million | $163.40 million | View | Listen | |
| 1/31/2013 | Q3 2013 | $0.23 | $0.34 | $130.81 million | $135.90 million | View | Listen | |
| 11/1/2012 | Q213 | $0.11 | $0.17 | $121.62 million | $124.00 million | View | N/A | |
| 7/26/2012 | | $0.16 | $0.39 | | | View | N/A | |
| 5/17/2012 | | ($0.16) | ($0.14) | | | View | N/A | |
| 2/2/2012 | | ($0.21) | ($0.11) | | | View | N/A | |
| 11/3/2011 | | ($0.10) | ($0.22) | | | View | N/A | |
| 8/1/2011 | | ($0.11) | $0.02 | | | View | N/A | |
| 5/18/2011 | | ($0.14) | ($0.14) | | | View | N/A | |
| 2/3/2011 | | ($0.15) | ($0.06) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Alkermes PLC (NASDAQ:ALKS)| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q2 2017 | 1 | ($0.16) | ($0.16) | ($0.16) |
| Q3 2017 | 1 | ($0.15) | ($0.15) | ($0.15) |
| Q4 2017 | 2 | ($0.10) | ($0.05) | ($0.08) |
(Data provided by Zacks Investment Research)
Dividend History for Alkermes PLC (NASDAQ:ALKS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Alkermes PLC (NASDAQ:ALKS)Insider Ownership Percentage: 5.34%
Institutional Ownership Percentage: 99.07%
Insider Trades by Quarter for Alkermes PLC (NASDAQ:ALKS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/11/2017 | Kathryn L Biberstein | CAO | Sell | 13,566 | $51.29 | $695,800.14 | |
| 9/1/2017 | Paul J Mitchell | Director | Sell | 1,500 | $50.77 | $76,155.00 | |
| 8/1/2017 | Paul J Mitchell | Director | Sell | 1,500 | $54.91 | $82,365.00 | |
| 7/3/2017 | Paul J Mitchell | Director | Sell | 1,500 | $58.11 | $87,165.00 | |
| 6/8/2017 | Shane Cooke | Insider | Sell | 10,000 | $60.33 | $603,300.00 | |
| 6/1/2017 | Paul J Mitchell | Director | Sell | 1,500 | $57.49 | $86,235.00 | |
| 5/24/2017 | Richard F Pops | Director | Sell | 25,000 | $57.42 | $1,435,500.00 | |
| 5/18/2017 | Michael J Landine | SVP | Sell | 10,000 | $57.23 | $572,300.00 | |
| 5/17/2017 | Richard F Pops | Director | Sell | 50,000 | $58.19 | $2,909,500.00 | |
| 5/11/2017 | Michael J Landine | SVP | Sell | 10,000 | $57.01 | $570,100.00 | |
| 5/10/2017 | Richard F Pops | Director | Sell | 25,000 | $57.29 | $1,432,250.00 | |
| 5/4/2017 | Shane Cooke | Insider | Sell | 6,500 | $60.05 | $390,325.00 | |
| 4/17/2017 | Elliot Ehrich | CMO | Sell | 10,000 | $56.60 | $566,000.00 | |
| 4/3/2017 | Kathryn L Biberstein | CAO | Sell | 15,000 | $57.68 | $865,200.00 | |
| 4/3/2017 | Paul J Mitchell | Director | Sell | 1,500 | $58.31 | $87,465.00 | |
| 3/29/2017 | Shane Cooke | Insider | Sell | 2,070 | $60.00 | $124,200.00 | |
| 3/23/2017 | Shane Cooke | Insider | Sell | 6,030 | $60.01 | $361,860.30 | |
| 3/21/2017 | Shane Cooke | Insider | Sell | 1,900 | $60.09 | $114,171.00 | |
| 3/20/2017 | Shane Cooke | Insider | Sell | 300 | $60.00 | $18,000.00 | |
| 3/15/2017 | Elliot Ehrich | CMO | Sell | 11,000 | $56.74 | $624,140.00 | |
| 3/7/2017 | James M Frates | SVP | Sell | 25,000 | $59.08 | $1,477,000.00 | |
| 3/2/2017 | Robert A Breyer | Director | Sell | 4,000 | $60.00 | $240,000.00 | |
| 3/2/2017 | Shane Cooke | Insider | Sell | 20,000 | $60.00 | $1,200,000.00 | |
| 3/1/2017 | Paul J Mitchell | Director | Sell | 1,500 | $57.06 | $85,590.00 | |
| 2/16/2017 | Elliot Ehrich | CMO | Sell | 11,000 | $56.68 | $623,480.00 | |
| 2/1/2017 | Paul J Mitchell | Director | Sell | 1,500 | $54.45 | $81,675.00 | |
| 1/17/2017 | Elliot Ehrich | CMO | Sell | 11,983 | $54.32 | $650,916.56 | |
| 1/9/2017 | Mark Stejbach | SVP | Sell | 547 | $60.27 | $32,967.69 | |
| 1/9/2017 | Shane Cooke | Insider | Sell | 550 | $60.27 | $33,148.50 | |
| 1/6/2017 | Elliot Ehrich | CMO | Sell | 10,000 | $59.44 | $594,400.00 | |
| 1/6/2017 | Mark Stejbach | SVP | Sell | 9,453 | $60.05 | $567,652.65 | |
| 1/6/2017 | Shane Cooke | Insider | Sell | 9,450 | $60.06 | $567,567.00 | |
| 1/4/2017 | Robert A Breyer | Director | Sell | 4,000 | $60.00 | $240,000.00 | |
| 1/3/2017 | David Joseph Gaffin | SVP | Sell | 2,500 | $55.40 | $138,500.00 | |
| 1/3/2017 | Paul J Mitchell | Director | Sell | 1,500 | $55.40 | $83,100.00 | |
| 12/16/2016 | Gordon G Pugh | COO | Sell | 21,458 | $57.65 | $1,237,053.70 | |
| 12/15/2016 | Elliot Ehrich | CMO | Sell | 5,000 | $55.99 | $279,950.00 | |
| 12/14/2016 | James M Frates | SVP | Sell | 25,000 | $54.73 | $1,368,250.00 | |
| 12/12/2016 | Elliot Ehrich | CMO | Sell | 16,983 | $55.15 | $936,612.45 | |
| 12/8/2016 | Kathryn L Biberstein | CAO | Sell | 14,145 | $56.13 | $793,958.85 | |
| 12/7/2016 | James M. Frates | SVP | Sell | 23,731 | $56.28 | $1,335,580.68 | |
| 12/1/2016 | Kathryn L Biberstein | CAO | Sell | 15,000 | $56.13 | $841,950.00 | |
| 11/30/2016 | Michael J Landine | SVP | Sell | 10,000 | $57.51 | $575,100.00 | |
| 11/29/2016 | Richard F Pops | Director | Sell | 30,000 | $56.98 | $1,709,400.00 | |
| 11/22/2016 | Richard F Pops | Director | Sell | 30,000 | $58.66 | $1,759,800.00 | |
| 10/4/2016 | Paul J Mitchell | Director | Sell | 2,000 | $47.42 | $94,840.00 | |
| 9/22/2016 | Elliot Ehrich | CMO | Sell | 5,000 | $50.83 | $254,150.00 | |
| 9/16/2016 | Elliot Ehrich | CMO | Sell | 5,000 | $48.87 | $244,350.00 | |
| 9/6/2016 | David Joseph Gaffin | SVP | Sell | 2,382 | $45.92 | $109,381.44 | |
| 9/6/2016 | Elliot Ehrich | CMO | Sell | 10,000 | $46.02 | $460,200.00 | |
| 9/6/2016 | Iain Michael Brown | CAO | Sell | 29,976 | $45.92 | $1,376,497.92 | |
| 9/6/2016 | Paul J Mitchell | Director | Sell | 2,000 | $45.92 | $91,840.00 | |
| 8/4/2016 | Paul J Mitchell | Director | Sell | 2,000 | $49.48 | $98,960.00 | |
| 7/27/2016 | Elliot Ehrich | CMO | Sell | 35,199 | $51.95 | $1,828,588.05 | |
| 7/5/2016 | Paul J Mitchell | Director | Sell | 2,000 | $45.81 | $91,620.00 | |
| 6/6/2016 | Paul J Mitchell | Director | Sell | 2,000 | $44.98 | $89,960.00 | |
| 5/4/2016 | Paul J Mitchell | Director | Sell | 2,000 | $38.60 | $77,200.00 | |
| 4/20/2016 | Michael J Landine | SVP | Sell | 16,875 | $41.09 | $693,393.75 | |
| 4/19/2016 | Richard F Pops | CEO | Sell | 18,750 | $40.15 | $752,812.50 | |
| 4/18/2016 | Iain Michael Brown | CAO | Sell | 5,368 | $39.27 | $210,801.36 | |
| 4/13/2016 | Elliot Ehrich | CMO | Sell | 11,698 | $37.66 | $440,546.68 | |
| 4/12/2016 | Richard F Pops | CEO | Sell | 25,000 | $37.79 | $944,750.00 | |
| 4/4/2016 | Paul J Mitchell | Director | Sell | 2,000 | $35.65 | $71,300.00 | |
| 3/22/2016 | Richard F Pops | CEO | Sell | 25,000 | $31.77 | $794,250.00 | |
| 3/15/2016 | Richard F Pops | CEO | Sell | 25,000 | $31.40 | $785,000.00 | |
| 3/4/2016 | Paul J Mitchell | Director | Sell | 2,000 | $32.80 | $65,600.00 | |
| 3/3/2016 | David W Anstice | Director | Buy | 5,000 | $32.87 | $164,350.00 | |
| 2/4/2016 | Paul J. Mitchell | Director | Sell | 2,000 | $32.81 | $65,620.00 | |
| 1/4/2016 | Robert A Breyer | Director | Sell | 2,000 | $77.33 | $154,660.00 | |
| 12/28/2015 | Mark Stejbach | insider | Sell | 10,000 | $80.24 | $802,400.00 | |
| 12/23/2015 | Shane Cooke | insider | Sell | 18,000 | $77.23 | $1,390,140.00 | |
| 12/7/2015 | Michael J. Landine | SVP | Sell | 3,750 | $73.02 | $273,825.00 | |
| 12/7/2015 | Richard F. Pops | CEO | Sell | 37,500 | $72.06 | $2,702,250.00 | |
| 12/1/2015 | Mark Stejbach | insider | Sell | 18,000 | $72.18 | $1,299,240.00 | |
| 12/1/2015 | Michael J. Landine | SVP | Sell | 10,000 | $72.18 | $721,800.00 | |
| 12/1/2015 | Richard F. Pops | CEO | Sell | 50,000 | $72.29 | $3,614,500.00 | |
| 12/1/2015 | Robert A Breyer | Director | Sell | 2,000 | $73.46 | $146,920.00 | |
| 11/23/2015 | Shane Cooke | insider | Sell | 18,000 | $72.62 | $1,307,160.00 | |
| 11/2/2015 | Mark Stejbach | insider | Sell | 18,000 | $72.06 | $1,297,080.00 | |
| 11/2/2015 | Robert A Breyer | Director | Sell | 2,000 | $71.80 | $143,600.00 | |
| 10/29/2015 | Iain Michael Brown | CAO | Sell | 10,822 | $69.99 | $757,431.78 | |
| 10/23/2015 | Shane Cooke | insider | Sell | 18,000 | $62.03 | $1,116,540.00 | |
| 10/13/2015 | James M. Frates | CFO | Sell | 20,000 | $59.78 | $1,195,600.00 | |
| 10/2/2015 | Robert A. Breyer | Director | Sell | 2,000 | $60.00 | $120,000.00 | |
| 9/23/2015 | Shane Cooke | insider | Sell | 18,000 | $67.09 | $1,207,620.00 | |
| 9/17/2015 | Michael J. Landine | SVP | Sell | 10,000 | $71.20 | $712,000.00 | |
| 9/17/2015 | Richard F. Pops | CEO | Sell | 50,000 | $71.27 | $3,563,500.00 | |
| 9/15/2015 | James M. Frates | CFO | Sell | 20,000 | $71.10 | $1,422,000.00 | |
| 9/10/2015 | Michael J. Landine | SVP | Sell | 10,000 | $67.61 | $676,100.00 | |
| 9/10/2015 | Richard F. Pops | CEO | Sell | 50,000 | $67.57 | $3,378,500.00 | |
| 9/1/2015 | Robert A Breyer | Director | Sell | 2,000 | $61.43 | $122,860.00 | |
| 8/24/2015 | Shane Cooke | insider | Sell | 18,000 | $57.65 | $1,037,700.00 | |
| 7/23/2015 | Shane Cooke | Insider | Sell | 18,000 | $69.79 | $1,256,220.00 | |
| 7/20/2015 | Gordon G Pugh | COO | Sell | 18,750 | $70.10 | $1,314,375.00 | |
| 7/14/2015 | James M Frates | CFO | Sell | 20,000 | $65.79 | $1,315,800.00 | |
| 7/1/2015 | Gordon G Pugh | COO | Sell | 13,750 | $65.13 | $895,537.50 | |
| 7/1/2015 | Robert A Breyer | Director | Sell | 2,000 | $64.90 | $129,800.00 | |
| 6/23/2015 | Shane Cooke | Insider | Sell | 18,000 | $66.84 | $1,203,120.00 | |
| 6/17/2015 | Paul J Mitchell | Director | Sell | 15,500 | $65.10 | $1,009,050.00 | |
| 6/16/2015 | Gordon G Pugh | COO | Sell | 32,977 | $63.11 | $2,081,178.47 | |
| 6/16/2015 | James M Frates | CFO | Sell | 10,000 | $58.63 | $586,300.00 | |
| 6/1/2015 | Paul J Mitchell | Director | Sell | 1,500 | $60.78 | $91,170.00 | |
| 6/1/2015 | Rebecca Peterson | SVP | Sell | 21,983 | $60.05 | $1,320,079.15 | |
| 5/26/2015 | Rebecca Peterson | SVP | Sell | 1,322 | $60.49 | $79,967.78 | |
| 5/26/2015 | Shane Cooke | Insider | Sell | 18,000 | $60.31 | $1,085,580.00 | |
| 5/22/2015 | Rebecca Peterson | SVP | Sell | 28,558 | $61.71 | $1,762,314.18 | |
| 5/12/2015 | James M Frates | CFO | Sell | 10,000 | $59.34 | $593,400.00 | |
| 5/4/2015 | Robert A Breyer | Director | Sell | 2,000 | $60.00 | $120,000.00 | |
| 5/1/2015 | Paul J Mitchell | Director | Sell | 1,500 | $55.79 | $83,685.00 | |
| 4/23/2015 | Shane Cooke | Insider | Sell | 18,000 | $62.55 | $1,125,900.00 | |
| 4/21/2015 | Elliot Ehrich | CMO | Sell | 25,000 | $62.39 | $1,559,750.00 | |
| 4/15/2015 | Gordon G Pugh | COO | Sell | 13,750 | $63.21 | $869,137.50 | |
| 4/15/2015 | James M Frates | CFO | Sell | 10,000 | $62.42 | $624,200.00 | |
| 4/15/2015 | Paul J Mitchell | Director | Sell | 1,500 | $62.71 | $94,065.00 | |
| 4/1/2015 | Robert A Breyer | Director | Sell | 5,000 | $61.22 | $306,100.00 | |
| 3/23/2015 | Shane Cooke | Insider | Sell | 18,000 | $65.33 | $1,175,940.00 | |
| 3/16/2015 | Elliot Ehrich | CMO | Sell | 18,000 | $66.81 | $1,202,580.00 | |
| 3/10/2015 | James M Frates | CFO | Sell | 10,000 | $66.25 | $662,500.00 | |
| 3/5/2015 | Rebecca Peterson | SVP | Sell | 17,737 | $71.37 | $1,265,889.69 | |
| 3/2/2015 | Gordon G Pugh | COO | Sell | 15,000 | $71.39 | $1,070,850.00 | |
| 3/2/2015 | Robert A Breyer | Director | Sell | 5,000 | $70.86 | $354,300.00 | |
| 2/23/2015 | Shane Cooke | Insider | Sell | 18,000 | $74.29 | $1,337,220.00 | |
| 2/17/2015 | Elliot Ehrich | CMO | Sell | 18,000 | $70.87 | $1,275,660.00 | |
| 2/3/2015 | James M Frates | CFO | Sell | 10,000 | $70.83 | $708,300.00 | |
| 2/2/2015 | Gordon G Pugh | COO | Sell | 15,000 | $72.01 | $1,080,150.00 | |
| 2/2/2015 | Robert A Breyer | Director | Sell | 5,000 | $72.91 | $364,550.00 | |
| 1/26/2015 | Gordon G Pugh | COO | Sell | 15,000 | $70.02 | $1,050,300.00 | |
| 1/23/2015 | Shane Cooke | Insider | Sell | 118,000 | $69.13 | $8,157,340.00 | |
| 1/16/2015 | Floyd E Bloom | Director | Sell | 20,000 | $67.12 | $1,342,400.00 | |
| 1/15/2015 | Elliot Ehrich | CMO | Sell | 18,375 | $66.45 | $1,221,018.75 | |
| 1/15/2015 | James M Frates | CFO | Sell | 10,000 | $66.86 | $668,600.00 | |
| 1/7/2015 | Kathryn L Biberstein | SVP | Sell | 28,374 | $65.00 | $1,844,310.00 | |
| 1/2/2015 | Robert A Breyer | Director | Sell | 5,000 | $58.57 | $292,850.00 | |
| 12/11/2014 | Richard F Pops | CEO | Sell | 100,000 | $56.04 | $5,604,000.00 | |
| 12/10/2014 | James M Frates | CFO | Sell | 18,870 | $56.07 | $1,058,040.90 | |
| 12/9/2014 | Michael J Landine | SVP | Sell | 18,000 | $56.82 | $1,022,760.00 | |
| 12/5/2014 | Kathryn L Biberstein | SVP | Sell | 15,433 | $57.61 | $889,095.13 | |
| 12/1/2014 | Robert A Breyer | Director | Sell | 5,000 | $54.64 | $273,200.00 | |
| 11/19/2014 | James M Frates | CFO | Sell | 8,000 | $53.86 | $430,880.00 | |
| 11/13/2014 | Richard F Pops | CEO | Sell | 100,000 | $52.87 | $5,287,000.00 | |
| 11/7/2014 | James M Frates | CFO | Sell | 13,303 | $49.98 | $664,883.94 | |
| 11/6/2014 | Kathryn L Biberstein | SVP | Sell | 20,000 | $50.54 | $1,010,800.00 | |
| 11/3/2014 | Robert A Breyer | Director | Sell | 5,000 | $50.05 | $250,250.00 | |
| 10/23/2014 | Gordon G Pugh | COO | Sell | 14,577 | $45.00 | $655,965.00 | |
| 10/8/2014 | James M Frates | CFO | Sell | 16,000 | $41.00 | $656,000.00 | |
| 10/1/2014 | Robert A Breyer | Director | Sell | 5,000 | $42.59 | $212,950.00 | |
| 9/24/2014 | James M Frates | CFO | Sell | 16,000 | $45.29 | $724,640.00 | |
| 9/18/2014 | Michael J Landine | SVP | Sell | 15,000 | $45.60 | $684,000.00 | |
| 9/17/2014 | Gordon G Pugh | COO | Sell | 14,900 | $45.04 | $671,096.00 | |
| 9/17/2014 | Richard F Pops | CEO | Sell | 50,000 | $44.89 | $2,244,500.00 | |
| 9/10/2014 | James M Frates | CFO | Sell | 16,000 | $43.18 | $690,880.00 | |
| 9/2/2014 | Gordon G Pugh | COO | Sell | 1,100 | $45.08 | $49,588.00 | |
| 9/2/2014 | Robert A Breyer | Director | Sell | 5,000 | $45.12 | $225,600.00 | |
| 8/27/2014 | James M Frates | CFO | Sell | 16,000 | $45.08 | $721,280.00 | |
| 8/26/2014 | Gordon G Pugh | COO | Sell | 16,000 | $45.00 | $720,000.00 | |
| 8/13/2014 | James M Frates | CFO | Sell | 15,000 | $41.37 | $620,550.00 | |
| 8/11/2014 | Elliot Ehrich | CMO | Sell | 16,667 | $41.65 | $694,180.55 | |
| 8/4/2014 | Gordon G Pugh | COO | Sell | 23,250 | $43.20 | $1,004,400.00 | |
| 8/1/2014 | Robert A Breyer | Director | Sell | 5,000 | $42.53 | $212,650.00 | |
| 7/16/2014 | James M Frates | CFO | Sell | 8,000 | $46.50 | $372,000.00 | |
| 7/9/2014 | Elliot Ehrich | CMO | Sell | 16,667 | $47.41 | $790,182.47 | |
| 7/9/2014 | James M Frates | CFO | Sell | 7,000 | $47.41 | $331,870.00 | |
| 7/3/2014 | Michael J Landine | SVP | Sell | 7,000 | $51.31 | $359,170.00 | |
| 7/2/2014 | Richard F Pops | CEO | Sell | 50,000 | $51.69 | $2,584,500.00 | |
| 7/1/2014 | Gordon G Pugh | COO | Sell | 16,000 | $46.49 | $743,840.00 | |
| 7/1/2014 | Robert A Breyer | Director | Sell | 5,000 | $50.57 | $252,850.00 | |
| 6/26/2014 | Michael J Landine | SVP | Sell | 10,000 | $49.92 | $499,200.00 | |
| 6/25/2014 | James M Frates | CFO | Sell | 7,000 | $50.22 | $351,540.00 | |
| 6/25/2014 | Richard F Pops | CEO | Sell | 50,000 | $49.87 | $2,493,500.00 | |
| 6/20/2014 | Paul J Mitchell | Director | Sell | 17,000 | $50.00 | $850,000.00 | |
| 6/19/2014 | Elliot Ehrich | CMO | Sell | 17,282 | $47.10 | $813,982.20 | |
| 6/19/2014 | Michael J Landine | SVP | Sell | 10,000 | $47.01 | $470,100.00 | |
| 6/18/2014 | Richard F Pops | CEO | Sell | 50,000 | $46.72 | $2,336,000.00 | |
| 6/17/2014 | Kathryn L Biberstein | SVP | Sell | 8,400 | $47.41 | $398,244.00 | |
| 6/11/2014 | James M Frates | CFO | Sell | 7,000 | $47.72 | $334,040.00 | |
| 6/9/2014 | Elliot Ehrich | CMO | Sell | 16,667 | $48.15 | $802,516.05 | |
| 6/2/2014 | Gordon G Pugh | COO | Sell | 16,000 | $45.34 | $725,440.00 | |
| 6/2/2014 | Robert A Breyer | Director | Sell | 5,000 | $45.18 | $225,900.00 | |
| 5/30/2014 | Rebecca Peterson | SVP | Sell | 21,981 | $45.86 | $1,008,048.66 | |
| 5/23/2014 | Rebecca Peterson | SVP | Sell | 1,321 | $45.08 | $59,550.68 | |
| 5/22/2014 | Elliot Ehrich | CMO | Sell | 2,378 | $44.49 | $105,797.22 | |
| 5/22/2014 | Gordon Pugh | COO | Sell | 15,700 | $45.25 | $710,425.00 | |
| 5/22/2014 | Rebecca Peterson | SVP | Sell | 19,807 | $44.02 | $871,904.14 | |
| 5/21/2014 | Elliot Ehrich | CMO | Sell | 1,981 | $44.00 | $87,164.00 | |
| 5/21/2014 | James Frates | CFO | Sell | 7,000 | $44.30 | $310,100.00 | |
| 5/20/2014 | Rebecca Peterson | SVP | Sell | 20,307 | $44.05 | $894,523.35 | |
| 5/19/2014 | Elliot Ehrich | CMO | Sell | 2,206 | $43.55 | $96,071.30 | |
| 5/8/2014 | Floyd Bloom | Director | Sell | 10,000 | $46.16 | $461,600.00 | |
| 5/5/2014 | Robert Breyer | Director | Sell | 5,000 | $46.72 | $233,600.00 | |
| 5/1/2014 | Paul Mitchell | Director | Sell | 1,000 | $45.90 | $45,900.00 | |
| 4/9/2014 | James Frates | CFO | Sell | 7,000 | $42.91 | $300,370.00 | |
| 4/1/2014 | Paul Mitchell | Director | Sell | 1,500 | $44.14 | $66,210.00 | |
| 3/19/2014 | James Frates | CFO | Sell | 7,000 | $46.84 | $327,880.00 | |
| 3/11/2014 | Wendy Dixon | Director | Buy | 1,600 | $47.37 | $75,792.00 | |
| 3/5/2014 | James Frates | CFO | Sell | 7,000 | $47.78 | $334,460.00 | |
| 2/18/2014 | Elliot Ehrich | CMO | Sell | 7,718 | $52.45 | $404,809.10 | |
| 2/3/2014 | Paul Mitchell | Director | Sell | 1,500 | $48.15 | $72,225.00 | |
| 1/21/2014 | Elliot Ehrich | CMO | Sell | 7,718 | $48.61 | $375,171.98 | |
| 1/16/2014 | Elliot Ehrich | CMO | Sell | 14,555 | $47.35 | $689,179.25 | |
| 1/16/2014 | Gordon Pugh | COO | Sell | 30,000 | $47.16 | $1,414,800.00 | |
| 1/16/2014 | James Frates | CFO | Sell | 7,000 | $47.40 | $331,800.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Alkermes PLC (NASDAQ:ALKS)
Latest Headlines for Alkermes PLC (NASDAQ:ALKS)
| Source: |
|
| Date | Headline |
|---|
 | Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia
finance.yahoo.com - September 19 at 8:46 PM |
 | Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia - Nasdaq
www.nasdaq.com - September 19 at 3:45 PM |
| Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia
finance.yahoo.com - September 19 at 3:44 PM |
 | Alkermes plc (ALKS) Says Patients Switched to its ARISTADA Showed Significant ...
www.streetinsider.com - September 19 at 2:09 AM |
| Patients Switched to Alkermes’ ARISTADA® Showed Significant Improvement in Schizophrenia Symptoms After Inadequate Response or Intolerance to INVEGA SUSTENNA®
finance.yahoo.com - September 19 at 2:09 AM |
| Alkermes plc (ALKS) Says Patients Switched to its ARISTADA ... - StreetInsider.com
www.streetinsider.com - September 18 at 4:07 PM |
 | Alkermes PLC (ALKS) Expected to Announce Earnings of $0.01 Per Share
www.americanbankingnews.com - September 14 at 4:14 PM |
| Alkermes PLC (ALKS) CAO Sells $695,800.14 in Stock
www.americanbankingnews.com - September 13 at 7:38 PM |
| Alkermes Announces 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders
finance.yahoo.com - September 6 at 3:41 PM |
| Alkermes PLC (ALKS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - September 6 at 8:32 AM |
| Alkermes PLC (ALKS) Director Sells $76,155.00 in Stock
www.americanbankingnews.com - September 5 at 8:34 PM |
 | Alkermes to Present Clinical and Real-World Data at Upcoming 30 th Annual Psych Congress
www.businesswire.com - September 5 at 5:10 PM |
| Alkermes is Now Oversold (ALKS)
www.nasdaq.com - September 5 at 5:10 PM |
| Alkermes to Present Clinical and Real-World Data at Upcoming 30th Annual Psych Congress
finance.yahoo.com - September 5 at 5:10 PM |
| Alkermes to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
finance.yahoo.com - September 5 at 5:10 PM |
| Alkermes PLC (ALKS) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - September 3 at 10:46 PM |
| Zacks: Analysts Anticipate Alkermes PLC (ALKS) Will Announce Quarterly Sales of $234.90 Million
www.americanbankingnews.com - August 29 at 11:42 AM |
| Alkermes PLC (ALKS) Given a $69.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - August 26 at 11:02 AM |
 | 3 Things In Biotech You Should Learn Today: August 23, 2017
seekingalpha.com - August 23 at 3:46 PM |
| Alkermes Initiates Rolling Submission of Depression Drug - Nasdaq ... - Nasdaq
www.nasdaq.com - August 22 at 9:34 PM |
| Alkermes Initiates Rolling Submission of Depression Drug
finance.yahoo.com - August 22 at 4:31 PM |
| Alkermes Initiates NDA Submission Of ALKS 5461 For Major Depressive Disorder
www.nasdaq.com - August 21 at 3:54 PM |
| Alkermes plc (ALKS) Initiates Rolling Submission of NDA for ALKS 5461
www.streetinsider.com - August 21 at 3:54 PM |
 | BRIEF-Alkermes PLC says initiates rolling submission of ALKS 5461 NDA to U.S. FDA
www.reuters.com - August 21 at 3:54 PM |
| Alkermes Initiates Rolling Submission of ALKS 5461 New Drug Application for Major Depressive Disorder
finance.yahoo.com - August 21 at 3:54 PM |
| ETFs with exposure to Alkermes Plc : August 14, 2017
finance.yahoo.com - August 14 at 9:07 PM |
| Alkermes PLC (ALKS) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 12 at 11:58 AM |
| IHS Markit Score downgrades Alkermes PLC to 63 out of 100, ranking positively in only one out of three available IHS Markit categories.
finance.yahoo.com - August 12 at 2:54 AM |
| IHS Markit Score upgrades Alkermes PLC to 71 out of 100, despite ranking positively in only one IHS Markit category.
finance.yahoo.com - August 10 at 5:11 PM |
| $234.90 Million in Sales Expected for Alkermes PLC (NASDAQ:ALKS) This Quarter
www.americanbankingnews.com - August 10 at 8:58 AM |
| See what the IHS Markit Score report has to say about Alkermes PLC.
finance.yahoo.com - August 10 at 2:00 AM |
| Alkermes Enters Oversold Territory (ALKS) - Nasdaq
www.nasdaq.com - August 8 at 8:31 PM |
| Insider Selling: Alkermes PLC (ALKS) Director Sells 1,500 Shares of Stock
www.americanbankingnews.com - August 1 at 8:20 PM |
| Alkermes Plc :ALKS-US: Earnings Analysis: Q2, 2017 By the Numbers : July 31, 2017
finance.yahoo.com - July 31 at 3:49 PM |
| Alkermes (ALKS) Q2 Loss Narrower than Expected, Sales Beat - Nasdaq
www.nasdaq.com - July 30 at 3:31 PM |
| Alkermes (ALKS) Q2 Loss Narrower than Expected, Sales Beat
finance.yahoo.com - July 29 at 2:35 AM |
 | EARNINGS SUMMARY: Details of Alkermes plc Q2 Earnings Report
www.rttnews.com - July 28 at 1:26 AM |
| ALKS Crosses Below Key Moving Average Level
www.nasdaq.com - July 28 at 1:26 AM |
| Alkermes' (ALKS) CEO Richard Pops on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - July 28 at 1:26 AM |
| Edited Transcript of ALKS earnings conference call or presentation 27-Jul-17 12:30pm GMT
finance.yahoo.com - July 28 at 1:26 AM |
| Alkermes plc Reports Second Quarter 2017 Financial Results - Business Wire (press release)
www.businesswire.com - July 27 at 3:19 PM |
| Alkermes plc Reports Second Quarter 2017 Financial Results
finance.yahoo.com - July 27 at 3:19 PM |
| Alkermes reports 2Q loss
finance.yahoo.com - July 27 at 3:19 PM |
| Alkermes PLC (NASDAQ:ALKS) Posts Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - July 27 at 1:27 PM |
| ETFs with exposure to Alkermes Plc : July 24, 2017
finance.yahoo.com - July 24 at 6:29 PM |
| Alkermes to Host Conference Call to Discuss Second Quarter 2017 Financial Results
finance.yahoo.com - July 20 at 5:05 PM |
| We Did The Math FBT Can Go To $127 - Nasdaq
www.nasdaq.com - July 19 at 10:00 PM |
| Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : July 19, 2017
finance.yahoo.com - July 19 at 4:58 PM |
| Zacks: Brokerages Expect Alkermes PLC (ALKS) to Post -$0.26 EPS
www.americanbankingnews.com - July 19 at 2:34 PM |
| Alkermes PLC (ALKS) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 19 at 8:15 AM |
Alkermes PLC (ALKS) Chart for Sunday, September, 24, 2017
